Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
- Close
- COMPANY OVERVIEW
- MANAGEMENT
- BOARD OF DIRECTORS
AREAS OF FOCUS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
- STORIES
CONTACT US

Main Content

Slide

AKARI THERAPEUTICS IS AN INNOVATIVE TARGETED

ONCOLOGY COMPANY BUILT ON NEXT GENERATION

ANTIBODY-DRUG CONJUGATES (ADC)

CORPORATE PRESENTATION CORPORATE PRESENTATION

AND A NOVEL DISCOVERY ENGINE

ANNUAL GENERAL MEETING ANNUAL GENERAL MEETING

RECENT PRESS RELEASES

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India Patent

June 25, 2025

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

June 18, 2025

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 29, 2025

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025

Footer

Follow Us

Privacy Statement

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.